A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2021-12-03 / Clin Cancer Res 2021 Dec;Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy
/in Dendritic Cells, International Publications, Prostate Cancer /von 2021-11-11 / Prostate 2021 Nov;Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, NSCLC, SCLC /von 2021-11-02 / Cancers (Basel) 2021 Nov;13(21)Recent Advances in Experimental Dendritic Cell Vaccines for Cancer
/in Dendritic Cells, International Publications /von 2021-09-23 / Front Oncol 2021;11:730824Targeting CD166 lung cancer stem cells: Molecular study using murine dendritic cell vaccine
/in Dendritic Cells, International Publications, NSCLC, SCLC /von 2021-08-23 / Toxicol Appl Pharmacol 2021 Oct;429:115699Long-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-08-09 / J Clin Oncol 39, 2021 (suppl 15; abstr 2618)Phase 1 trial of autologous dendritic cell vaccination with imiquimod immunomodulation in children and adults with refractory sarcoma.
/in Dendritic Cells, International Publications, Soft Tissue Sarcoma /von 2021-08-09 / J Clin Oncol 39, 2021 (suppl 15; abstr 11542)Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-08-01 / Melanoma Res 2021 08;31(4):378-388Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2021-07-20 / Gynecol Oncol 2021 Sep;162(3):652-660
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus
- Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
- A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma